NEW YORK , NY / ACCESSWIRE / January 24, 2018 / The S&P 500 Index and Nasdaq rose to new records Tuesday on upbeat earnings. The S&P 500 Index gained 0.22 percent to close at a record 2,839.13, while the Nasdaq Composite Index spiked 0.71 percent to close at a record 7,460.29. The Dow Jones Industrial touch an intraday record of 26,246.19 before closing at 26,210.81, a decrease of 0.01 percent.
"Stocks will continue to benefit from the earnings driven bull market that we have experienced over the past 18 months both in the U.S. and abroad," said Marc Chaikin, CEO of Chaikin Analytics, according to CNBC.
RDI Initiates Coverage on:
Exact Sciences Corporation
Ultragenyx Pharmaceutical Inc.
Exact Sciences stock jumped 7.55% Tuesday, to close the day at $52.15. The stock recorded a trading volume of 3,610,411 shares, which was above its three months average volume of 2,270,270 shares. In the last year, Exact Sciences shares have traded in a range of 16.95 - 63.60. The share price has gained 207.67% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $52.65 is greater than its 200-day moving average of $47.62. Shares of Exact Sciences have gained roughly 0.25 percent in the past month and are down 0.74 percent year-to-date.
Access RDI's Exact Sciences Corporation Research Report at:
On Tuesday, shares in Ultragenyx Pharmaceutical recorded a trading volume of 1,638,854 shares, which was above the three months average volume of 478,196 shares. The stock ended the day 8.90% higher at 58.14. The share price has gained 34.77% from its 52-week low with a 52-week trading range of 43.14 - 91.35. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $47.77 is below its 200-day moving average of $53.40. Shares of Ultragenyx Pharmaceutical have gained roughly 21.05 percent in the past month and are up 25.36 percent year-to-date.
Access RDI's Ultragenyx Pharmaceutical Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.